World's Best Scientists 2026 revealed!

D-Index & Metrics

Biology and Biochemistry

D-Index
65
Citations
23018
World Ranking
8974
National Ranking
3987

Jason J. Luke publication distribution in Biology and Biochemistry in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Biology and Biochemistry in 2026. The highlighted bar marks where Jason J. Luke sits on this spectrum.

47–56 publications: 8 scientists 57–66 publications: 35 scientists 67–76 publications: 106 scientists 77–86 publications: 231 scientists 87–96 publications: 414 scientists 97–106 publications: 546 scientists 107–116 publications: 704 scientists 117–126 publications: 849 scientists 127–136 publications: 980 scientists 137–146 publications: 942 scientists 147–156 publications: 969 scientists 157–166 publications: 950 scientists 167–176 publications: 951 scientists 177–186 publications: 915 scientists 187–196 publications: 787 scientists 197–206 publications: 841 scientists 207–216 publications: 735 scientists 217–226 publications: 709 scientists 227–236 publications: 651 scientists 237–246 publications: 605 scientists 247–256 publications: 510 scientists 257–266 publications: 524 scientists 267–276 publications: 434 scientists 277–286 publications: 418 scientists 287–296 publications: 350 scientists 297–306 publications: 363 scientists 307–316 publications: 315 scientists 317–326 publications: 296 scientists 327–336 publications: 261 scientists 337–346 publications: 240 scientists 347–356 publications: 219 scientists 357–366 publications: 197 scientists 367–376 publications: 154 scientists 377–386 publications: 161 scientists 387–396 publications: 155 scientists 397–406 publications: 145 scientists 407–416 publications: 124 scientists 417–426 publications: 112 scientists 427–436 publications: 132 scientists 437–446 publications: 116 scientists 447–456 publications: 99 scientists 457–466 publications: 81 scientists 467–476 publications: 91 scientists 477–486 publications: 80 scientists 487–496 publications: 80 scientists 497–506 publications: 60 scientists 507–516 publications: 36 scientists 517–526 publications: 46 scientists 527–536 publications: 54 scientists 537–546 publications: 44 scientists 547–556 publications: 43 scientists 557–566 publications: 43 scientists 567–576 publications: 42 scientists 577–586 publications: 25 scientists 587–596 publications: 34 scientists 597–606 publications: 23 scientists 607–616 publications: 33 scientists 617–626 publications: 31 scientists 627–636 publications: 27 scientists 637–646 publications: 25 scientists 647–656 publications: 28 scientists 657–666 publications: 34 scientists 667–676 publications: 18 scientists 677–686 publications: 16 scientists 687–696 publications: 10 scientists 697–706 publications: 12 scientists 707–716 publications: 21 scientists 717–726 publications: 12 scientists 727–736 publications: 12 scientists 737–746 publications: 10 scientists 747–756 publications: 7 scientists 757–766 publications: 13 scientists 767–776 publications: 15 scientists 777–786 publications: 13 scientists 787–796 publications: 9 scientists 797–806 publications: 9 scientists 807–816 publications: 7 scientists 817–826 publications: 4 scientists 827–836 publications: 9 scientists 837–846 publications: 7 scientists 847–856 publications: 3 scientists 857–866 publications: 5 scientists 867–876 publications: 5 scientists 877–886 publications: 11 scientists 887–896 publications: 3 scientists 897–906 publications: 4 scientists 907–916 publications: 7 scientists 917–926 publications: 5 scientists 927–936 publications: 6 scientists 937–946 publications: 6 scientists 947–956 publications: 3 scientists 957–966 publications: 7 scientists 967–976 publications: 2 scientists 977–986 publications: 2 scientists 987–996 publications: 1 scientists 997–1,006 publications: 5 scientists 1,007–1,016 publications: 2 scientists 1,017–1,026 publications: 2 scientists 1,027 publications: 1 scientists 1,028+ publications: 100 scientists
47 publications 1,028+

This scientist: 702 publications — 98th percentile

98% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,028 publications or more.

Jason J. Luke D-index placement in Biology and Biochemistry in 2026

The chart shows the D-index (discipline H-index) distribution of Biology and Biochemistry scientists ranked by Research.com in 2026. The highlighted bar marks where Jason J. Luke sits on this spectrum.

40–41 D-Index: 80 scientists 42–43 D-Index: 183 scientists 44–45 D-Index: 317 scientists 46–47 D-Index: 504 scientists 48–49 D-Index: 718 scientists 50–51 D-Index: 900 scientists 52–53 D-Index: 1,026 scientists 54–55 D-Index: 1,150 scientists 56–57 D-Index: 1,236 scientists 58–59 D-Index: 1,253 scientists 60–61 D-Index: 1,163 scientists 62–63 D-Index: 1,131 scientists 64–65 D-Index: 1,032 scientists 66–67 D-Index: 897 scientists 68–69 D-Index: 814 scientists 70–71 D-Index: 715 scientists 72–73 D-Index: 709 scientists 74–75 D-Index: 596 scientists 76–77 D-Index: 512 scientists 78–79 D-Index: 473 scientists 80–81 D-Index: 412 scientists 82–83 D-Index: 373 scientists 84–85 D-Index: 358 scientists 86–87 D-Index: 285 scientists 88–89 D-Index: 273 scientists 90–91 D-Index: 227 scientists 92–93 D-Index: 208 scientists 94–95 D-Index: 193 scientists 96–97 D-Index: 153 scientists 98–99 D-Index: 157 scientists 100–101 D-Index: 148 scientists 102–103 D-Index: 120 scientists 104–105 D-Index: 113 scientists 106–107 D-Index: 100 scientists 108–109 D-Index: 86 scientists 110–111 D-Index: 67 scientists 112–113 D-Index: 72 scientists 114–115 D-Index: 73 scientists 116–117 D-Index: 64 scientists 118–119 D-Index: 53 scientists 120–121 D-Index: 60 scientists 122–123 D-Index: 54 scientists 124–125 D-Index: 43 scientists 126–127 D-Index: 38 scientists 128–129 D-Index: 49 scientists 130–131 D-Index: 26 scientists 132–133 D-Index: 18 scientists 134–135 D-Index: 23 scientists 136–137 D-Index: 32 scientists 138–139 D-Index: 32 scientists 140–141 D-Index: 27 scientists 142–143 D-Index: 19 scientists 144–145 D-Index: 22 scientists 146–147 D-Index: 12 scientists 148–149 D-Index: 16 scientists 150–151 D-Index: 14 scientists 152–153 D-Index: 10 scientists 154–155 D-Index: 13 scientists 156–157 D-Index: 10 scientists 158–159 D-Index: 7 scientists 160–161 D-Index: 9 scientists 162–163 D-Index: 13 scientists 164–165 D-Index: 4 scientists 166 D-Index: 4 scientists 167+ D-Index: 98 scientists
40 D-Index 167+

This scientist: 65 D-Index — 55th percentile

55% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 167 D-Index or more.

Overview

Jason J. Luke is affiliated with the University of Pittsburgh in the United States. Their research predominantly spans the fields of Medicine and Immunology and Microbiology, with a focus on Oncology, Immunology, Molecular Biology, Pulmonary and Respiratory Medicine, and Cancer Research as key subfields.

The main topics covered in their work include:

  • Cancer Immunotherapy and Biomarkers
  • CAR-T cell therapy research
  • Immunotherapy and Immune Responses
  • Cutaneous Melanoma Detection and Management
  • Melanoma and MAPK Pathways
  • Cancer Research and Treatments
  • Interferon and immune responses

Jason J. Luke has contributed extensively to academic literature, with frequent publications appearing in these venues:

  • Journal of Clinical Oncology
  • Regular and Young Investigator Award Abstracts
  • Clinical Cancer Research
  • Journal for ImmunoTherapy of Cancer
  • Cancer Research

Some of their recent papers include:

  • Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study, 2024, The Lancet
  • Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma, 2020, Cancer Cell
  • STING Agonists as Cancer Therapeutics, 2021, Cancers
  • Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas, 2021, Clinical Cancer Research
  • Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma, 2021, Journal of Clinical Oncology

Jason J. Luke frequently collaborates with several co-authors, including:

  • Riyue Bao
  • Diwakar Davar
  • John M. Kirkwood
  • Georgina V. Long
  • Yana G. Najjar

Best Publications

  • The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients

    Vyara Matson;Jessica Fessler;Riyue Bao;Tara Chongsuwat

  • Managing toxicities associated with immune checkpoint inhibitors: Consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group

    I. Puzanov;A. Diab;K. Abdallah;C. O. Bingham

  • Targeted agents and immunotherapies: optimizing outcomes in melanoma.

    Jason J. Luke;Keith T. Flaherty;Antoni Ribas;Georgina V. Long;Georgina V. Long

  • Safety and Efficacy of Durvalumab (MEDI4736), an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer

    Christophe Massard;Michael S. Gordon;Sunil Sharma;Saeed Rafii

  • Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA

    Geoffrey R Oxnard;Cloud P Paweletz;Yanan Kuang;Stacy L Mach

  • WNT/β-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers

    Jason J. Luke;Riyue Bao;Randy F. Sweis;Stefani Spranger

  • Imatinib for Melanomas Harboring Mutationally Activated or Amplified KIT Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin

    F. Stephen Hodi;Christopher L. Corless;Anita Giobbie-Hurder;Jonathan A. Fletcher

  • Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors.

    Jason J. Luke;Jeffrey M. Lemons;Theodore G. Karrison;Sean P. Pitroda

  • Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy.

    Lucie Heinzerling;Patrick A. Ott;F. Stephen Hodi;Aliya N. Husain

  • Density of immunogenic antigens does not explain the presence or absence of the T-cell-inflamed tumor microenvironment in melanoma.

    Stefani Spranger;Jason J Luke;Riyue Bao;Yuanyuan Zha

  • Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma

    Catherine S. Grasso;Catherine S. Grasso;Jennifer Tsoi;Mykola Onyshchenko;Gabriel Abril-Rodriguez

  • STING Agonists as Cancer Therapeutics.

    Afsaneh Amouzegar;Manoj Chelvanambi;Jessica N. Filderman;Walter J. Storkus

  • T Cell–Inflamed versus Non-T Cell–Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection

    Jonathan A. Trujillo;Randy F. Sweis;Riyue Bao;Jason J. Luke

  • Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037)

    Tara C Mitchell;Omid Hamid;David C Smith;Todd M Bauer

  • Reimagining IDO pathway inhibition in cancer immunotherapy via downstream focus on the tryptophan-kynurenine-aryl hydrocarbon axis

    Brian W. Labadie;Riyue Bao;Jason J. Luke

  • STING pathway agonism as a cancer therapeutic.

    Blake A. Flood;Emily F. Higgs;Shuyin Li;Jason J. Luke

  • The efficacy of anti-PD-1 agents in acral and mucosal melanoma.

    Alexander N. Shoushtari;Alexander N. Shoushtari;Rodrigo R. Munhoz;Deborah Kuk;Patrick A. Ott

  • Systemic High-Dose Corticosteroid Treatment Does Not Improve the Outcome of Ipilimumab-Related Hypophysitis: A Retrospective Cohort Study

    Le Min;Frank Stephen Hodi;Anita Giobbie-Hurder;Patrick A. Ott

  • Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer

    Lawrence Fong;Andrew Hotson;John D. Powderly;Mario Sznol

  • Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience.

    Jason J. Luke;Margaret K. Callahan;Michael A. Postow;Emanuela Romano

Frequent Co-Authors

Thomas F. Gajewski
Thomas F. Gajewski University of Chicago
F. Stephen Hodi
F. Stephen Hodi Harvard University
Patrick A. Ott
Patrick A. Ott Harvard University
Omid Hamid
Omid Hamid Cedars-Sinai Medical Center
Michael A. Postow
Michael A. Postow Memorial Sloan Kettering Cancer Center
Paolo A. Ascierto
Paolo A. Ascierto National Institutes of Health
Douglas B. Johnson
Douglas B. Johnson Vanderbilt University Medical Center
Igor Puzanov
Igor Puzanov Roswell Park Cancer Institute
Jedd D. Wolchok
Jedd D. Wolchok Cornell University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

A background in Biology or Biochemistry opens doors to several high-demand careers in healthcare and science. Many students pursue online programs for flexibility and accessibility. For example, those interested in diagnostic imaging can enroll in ultrasound tech programs online to train for roles as sonographers.

Another rewarding field is radiology. Students looking for entry-level opportunities can start with online radiology programs, which often offer affordable pathways to becoming a radiologic technologist.

For those passionate about nutrition and wellness, earning an advanced degree at one of the best schools for masters in nutrition can lead to fulfilling roles as registered dietitians or nutrition consultants.

Finally, aspiring healthcare professionals can consider online medical assistant programs with financial aid, which combine comprehensive training with financial support options.

Exploring these online degrees can help you find a pathway that complements your interests in Biology and Biochemistry, while offering flexibility for your individual needs.

Best Scientists Citing Jason J. Luke

Trending Scientists

Recently Published Articles